Tab Application Banner
  • Users Online: 513
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
ORIGINAL ARTICLE
Ahead of Print

The convergence of fibrosis and immune pathways: 5-HT2 and 5-HT2B antagonists attenuate profibrotic phenotype in human pancreatic stellate cells by modulating signal transducer and activator of transcription 3 phosphorylation


1 Department of Surgical Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
2 Department of Medical Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
3 Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

Correspondence Address:
Gaurav Pande,
Department of Medical Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/injr.injr_159_20

Background: Immune mechanisms are believed to play an important role in the pathogenesis of pancreatic inflammation and fibrosis. Transforming growth factor β1-mediated mechanisms are well known; however, an effective treatment option is yet not available. Serotonin (5-HT) is known to induce fibrosis in carcinoid tumors and diseases such as scleroderma and blocking 5-HT has shown promise in the attenuation of fibrosis in animal models of scleroderma. Herein, we evaluated the role of 5-HT in pancreatic fibrosis and its reversal with antagonists of 5-HT. Methodology: Pancreatic stellate cells (PSCs) were cultured from the two patients of pancreatic cancer undergoing pancreaticoduodenectomy. PSCs were cultured in the presence of 5-HT and as per the disease mimicking strategy (PSCs cultured with 5-HT first followed by 5-HT antagonist (terguride) and 5-HT2Bantagonist (SB204741) for 24 h and pretreatment strategy, PSCs treated with 5-HT antagonists first followed by 5-HT. mRNA expression of profibrotic genes (col1A1, Col1A2, ACTA-2, and CTGF) and Western blot analysis of signal transducer and activator of transcription 3 (STAT-3) and Smad-3 proteins was carried out. Results: 5-HT-induced profibrotic genes mRNA expression in PSCs was significantly reversed by 5-HT antagonists, terguride and SB204741, to a large extent. Pretreatment strategy was more effective in the amelioration of profibrotic potential. SB204741, 5-HT2Bantagonist was more effective than terguride. 5-HT antagonists mediated their effect by reducing the phosphorylation of noncanonical pathway mediator pSTAT3 more significantly then canonical pathway mediator pSmad-3. Conclusion: 5-HT induces profibrotic potential in human PSCs and inhibitors of 5-HT receptors, Terguride and SB 204,741 ameliorate it by reducing the phosphorylation of STAT-3 and Smad-3, more so in pretreatment strategy. 5-HT inhibitors may have a potential to ameliorate fibrosis in pancreas.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Sharma S
    -  Pande G
    -  Rai MK
    -  Misra DP
    -  Gupta L
    -  Agarwal V
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed68    
    PDF Downloaded4    

Recommend this journal